Summary A total of 301 colorectal carcinoma (CRC) archival samples were analysed using the amplification-refractory mutation system (ARMS). Each sample was examined to determine the mutation status of codons 12 and 13 of the K-ras oncogene. The results from direct DNA sequence analysis carried out on 30 of the samples differed from the ARMS result in almost 50% of the cases as a result of the relative excess of wild-type to mutated DNA sequences. To assess the validity of the ARMS data, the polymerase chain reaction (PCR) was used to generate an amplicon from K-ras exon from 23 of the samples. The PCR amplicons were cloned and sequenced, and the DNA sequence analysis of the cloned material was in agreement with the ARMS results in all but one case. This case represented a tumour that exhibited a five-nucleotide reversed inversion. The cloned sequence data confirm the sensitivity and specificity of the individual ARMS reactions and that it is possible in certain cases to detect additional, more complex, sequence variations.
Colorectal cancer is the second most common malignancy in the USA (Ries et al, 1994) and is a significant cause of morbidity and mortality world-wide. The American Cancer Society estimated that in 1995 more than 130 000 new cases of CRC would be diagnosed in the USA and that there would be 54 900 deaths from the disease (American Cancer Society, 1995) . CRC onset and its progression has been studied extensively at the molecular (Bos et al, 1987; Forrester et al, 1987; Vogelstein et al, 1988; Burmer and Loeb, 1989; Delattre et al, 1989; Kern et al, 1989; Vogelstein et al, 1989; Fearon and Vogelstein, 1990; El-Deiry et al, 1991; Oudejans et al, 1991; Houlston et al, 1992; Laurent-Puig et al, 1992; Offerhaus et al, 1992; Sharrard et al, 1992; Bell et al, 1993; Finkelstein et al, 1993a and b; McLellan et al, 1993; Peltomaki et al, 1993; Urosevic et al, 1993; Breivik et al, 1994; Dix et al, 1994; Moerkerk et al, 1994; Morrin et al, 1994; Tanaka et al, 1994; Giaretti et al, 1995; Laird et al, 1995; Lewis et al, 1996; Span et al, 1996) and genetic (Woolf et al, 1958; Macklin et al, 1960; Houlston et al, 1992; Zhao and Le Marchand, 1992; Peltomaki et al, 1993; Goldgar et al, 1994; Lewis et al, 1996) levels and there is a commonly accepted model relating tumour grade according to Dukes' stage (Dukes, 1932) to specific DNA changes (Fearon and Vogelstein, 1990) .
It has recently been concluded that reliable CRC screening procedures require development and that additional research is needed to identify mutated genes in blood and stool (Young and Levin, 1996) . Although there are many examples of nucleic acid changes having potential as tumour markers (Bos et al, 1987; Forrester et al, 1987; Vogelstein et al, 1988; Burmer and Loeb, 1989; Delattre et al, 1989; Kern et al, 1989; Vogelstein et al, 1989 ; Fearon and Vogelstein, 1990; Jones and Buckley, 1990; Capella et al, 1991; El-Deiry et al, 1991; Oudejans et al, 1991; Stork et al, 1991; Laurent-Puig et al, 1992; Offerhaus et al, 1992; Sharrard et al, 1992; Bell et al, 1993; Finkelstein et al, 1993a and b; McLellan et al, 1993; Urosevic et al, 1993; Breivik et al, 1994; Dix et al, 1994; Magewu and Jones, 1994; Moerkerk et al, 1994; Morrin et al, 1994; Tanaka et al, 1994; Giaretti et al, 1995; Laird et al, 1995; Span et al, 1996) , their value as clinical tools in cancer diagnosis, staging or even screening needs to be demonstrated and two important criteria must be met. First, adequate supplies of nucleic acid must be extracted from the clinical material; second, robust and accurate methods of analysis are required. For reliable tumour genotyping to be useful in disease staging, any test has to be adequately validated and there should be demonstrable benefits over current methods.
A significant proportion of CRCs have mutations in the K-ras oncogene (Bos et al, 1987; Forrester et al, 1987; Vogelstein et al, 1988; Burmer and Loeb, 1989; Delattre et al, 1989; Fearon and Vogelstein, 1990; Capella et al, 1991; Oudejans et al, 1991; Offerhaus et al, 1992; Bell et al, 1993; Finkelstein et al, 1993a and b; McLellan et al, 1993; Peltomaki et al, 1993; Urosevic et al, 1993; Breivik et al, 1994; Moerkerk et al, 1994; Morrin et al, 1994; Tanaka et al, 1994; Giaretti et al, 1995; Span et al, 1996) . We report a study using 301 DNA samples extracted from a colorectal tumour bank. In this study, mutations within codons 12 and 13 of the K-ras oncogene were investigated using amplification-refractory mutation system (ARMS) (Newton et al, 1989) . Direct DNA sequencing (Newton et al, 1988) and sequencing of cloned amplicons were then performed to assess the ARMS test results. In almost half of the cases, the direct sequencing result detected Kras wild-type sequence only, this was in contrast to the ARMS findings in which mutations in codons 12 and 13 were detected. However, when K-ras exon I amplicons were cloned into Escherichia coli, the ARMS result was consistently in accord with the sequence of the cloned material, with the exception of one tumour that harboured a mutation of five consecutive nucleotides, which was detected by three of the ARMS primers. Our data show that ARMS is a sensitive test for detecting under-represented nucleic acid sequences. We also demonstrate that the technique is ideally suited to the detection of tumour DNA markers supplying genotype information specific to prediagnosed tumours. Dukes' C (Dukes, 1932) . Each frozen specimen was sectioned by cryostat, 5 jim was taken for haematoxylin and eosin staining, three or four parallel 10-im sections were transferred to sterile tubes and stored at -70°C. Fresh blades were used for each sample. DNA extraction comprised thawing sections on ice and the addition of sufficient sterile lysis buffer (10 mM TrisHCl, pH 7.5, 20% sodium dodecyl sulphate, 50 jg ml-proteinase K) to saturate the material. After an ovemight digestion at 37°C, a standard phenol-chloroform purification and ethanol precipitation was carried out (Sambrook et al, 1989) . The resulting DNA was resuspended in 200 jil of 10 mm Tris-HCl (pH 7.5). DNA samples were then stored at -70°C before quantification and K-ras mutation analysis.
MATERIALS AND METHODS

K-ras mutation ARMS tests
Individual ARMS tests were developed to detect specific point mutations in the K-ras oncogene. The 3'-terminal base of each of seven ARMS oligonucleotide primers was complementary to one of the common mutations of codons 12 or 13 of the K-ras oncogene occurring in CRCs (Breivik et al, 1994) (Figure 1 ). In addition to the ARMS primers, a common primer complementary to the K-ras intron sequence was included (Figure 1) . Two other primer pairs were also present in each test to give amplification control products. Their sequences were: 5'-TATATGTGCCATGG-GGCCTGTGCAAGGAAG-3' and 5'-CTCCTACACCCAGCCATlTFTTGGC-3', which amplify part of exon IV of the cystic fibrosis transmembrane conductance regulator (CFTR) gene (Riordan et al, 1989) , and 5'-GGGCCTCAGTCCCAACATGGC-TAAGAGGTG-3' and 5'-CCCACCTTCCCCTCTCTCCAGG-CAAATGGG-3', which amplify a part of each of exon II and intron III of the human ax-antitrypsin gene (Newton et al, 1988) .
Normal human DNA was extracted from the blood of healthy volunteers (Ferrie et al, 1992) . K-ras mutated DNA samples were extracted from tumour derived cell lines as shown in Table 1 . The K-ras mutation for each cell line DNA was confirmed by direct DNA sequencing as described below for tumour-derived DNA samples. The cell line DNAs were then used to define amplification conditions that conferred specificity to each ARMS reaction when the following criteria were applied. First, after the DNA 
A(Asp) Figure 1 The K-ras genomic DNA sequence; wild-type codons 12 and 13 are shown in bold type and underlined. Filled arrows (-* and *-) identify the 3' end of the ARMS primers designed to amplify individual K-ras-mutated sequences. Open arrows (=> and 4=) identify the 3' ends of the flanking intron. The ARMS primers were designed to detect K-ras codon 12 glycine (GGT) to arginine (CGT), cysteine (TGT), serine (AGT), valine (GTT), aspartic acid (GAT) and alanine (GCT) changes and the codon 13 glycine (GGC) to aspartic acid (GAC) point mutation (23). The direction of the arrow heads represent sense (-4 and >) and antisense (*-and =) primers. ARMS reaction products derived from the intron-specific primer cpA (X) and any of the antisense ARMS prmers (*-) are 158 bp (codon 12 mutations) or 161 bp (codon 13 mutation). ARMS amplicons derved from the intron-specific primer cpB (#) and any of the sense ARMS primers (-4) are 190 bp amplification reaction and agarose gel electrophoresis in the presence of 0.5 jg ml ethidium bromide (Sambrook et al, 1989) (Kwok and Higuchi, 1989) .
The amount of DNA extracted from each tumour sample was measured by fluorescence after intercalation of the Hoechst 33258 dye (Riley et al, 1989) . ARMS reactions containing these DNAs
(1 jIl each) were performed in 50 jil of buffer comprising 10 mM Tris-HCl, pH 8.3, 1.2 mm magnesium chloride, 50 mM potassium chloride, 0.01% gelatin and dNTPs (100 mm each). The reactions also contained mutation-specific and the appropriate intronspecific primers (1 jM each) as shown in Figure 1 (50 p1) and amplified over 35 cycles of 94'C, 60°C, 72°C (1 min each). After electrophoresis through a 2% metaphor agarose gel (FMC Bioproducts), the exon I bands were excised and purified using a Wizard DNA purification kit (Promega). Typical yields were 1-5 gg in 50,l. The purified products were sequenced by direct incorporation of [a35-S]dATP (Amersham) using a modified version (Green et al, 1989 ) of the Sequenase 2.0 DNA sequencing kit (Amersham). Annealing mixtures also contained template DNA (6 pl), sequencing primer (1 pl, 500 ng) and dimethyl sulphoxide (1 pl), (Sigma). Each labelling reaction was supplemented with 0.2 u of DNA polymerase I, Klenow fragment (labelling grade, Boehringer Mannheim; Redston et al, 1994) . Sequencing reactions were run on 6% polyacrylamide gels that were subsequently dried and autoradiographed.
K-ras ARMS test validation: cloning and sequencing of tumour DNAs
An aliquot of each amplicon prepared for direct DNA sequencing was also ligated into the vector pGEM-T (Promega) at 17°C overnight. A 2 pl aliquot from each ligation mixture was used to transform competent Escherichia coli JM109 cells (Promega). These were plated and blue/white screened according to the supplier's instructions. White colonies were picked into 10 ml of sterile distilled water. PCR using the conditions described above, but for 25 cycles, was carried out to test simultaneously for the presence of an insert and the K-ras mutation status of any insert. The amplimers in each reaction were the M13 5'-GTTTTCCCA-GTCACGAC-3' (forward), 5'-CAGGAAACAGCTATGAC-3' (reverse) primers and the ARMS primer that initially identified the mutation. Amplification products were then visualized on a 3% agarose gel. Clones with inserts detected by the PCR screen were picked into 1 ml of LB broth and grown overnight at 37°C. An aliquot (100 pl) from each was inoculated into a further 1 ml of broth and grown for 3-4 h at 37°C. Ten p.f.u. per cell of M13KO7 helper phage was then added to each culture. After 1 h at room temperature, LB broth (9 ml) containing 70 mg ml-kanamycin and 100 mg ml-ampicillin was added and the culture incubated overnight at 37°C. Virus particles were isolated by polyethylene glycol 6000/sodium chloride precipitation, and single-stranded DNA was isolated by phenol-chloroform extraction followed by ethanol precipitation (Sambrook et al, 1989) . DNA sequencing was performed using the M13 forward primer as described above.
RESULTS
Histological analyses
Histological examination of the haematoxylin and eosin-stained material confirmed the presence of tumour cells in at least 90% of the sample in each case (data not shown).
ARMS test development
Thermal cycling and primer annealing conditions were determined empirically, having imposed the specificity criteria described above; these are shown in Table 2 . An example showing the specificity of each of four of the tests is shown in Figure 2 . Figure 3 . A summary of the K-ras mutations detected using ARMS, the Dukes' stage of the tumour and the direct DNA sequencing result for 30 of the tumour DNAs examined is shown in Table 3 .
Quantitative analysis of K-ras mutations
Three primer PCR results used to classify clones from a selection of tumour DNAs are shown in Figure 4 . Table 4 provides an analysis of the ARMS data, direct DNA sequencing and clone analyses from equivalent samples.
K-ras mutational analysis of the 301 tumour bank samples
As the majority of CRCs were classified as either Dukes' B or C at the time of surgery, a relatively smaller number of Dukes' A (31 in Table 5 shows the results based on which the K-ras codons 12 and 13 mutational analysis was made and the relative K-ras mutation frequencies.
DISCUSSION
Many studies have examined the association of K-ras mutations with CRC (Bos et al, 1987; Forrester et al, 1987; Vogelstein et al, 1988; Bos, 1989; Burmer and Loeb, 1989; Vogelstein et al, 1989; Capella et al, 1991; Oudejans et al, 1991; Sidransky et al, 1992; Bell et al, 1993; Finkelstein et al, 1993a and b; McLellan et al, 1993; Urosevic et al, 1993; Breivik et al, 1994; Moerkerk et al, 1994; Morrin et al, 1994; Giaretti et al, 1995; Hasegawa et al, 1995; Hayashi et al, 1995; Ranaldi et al, 1995; Carpenter et al, 1996; Span et al, 1996; Villa et al, 1996) . However, there are significant differences in reported frequencies of K-ras mutations in CRC (McLellan et al, 1993) . Inconsistencies between studies could be due to one or more of several factors. These include the number of tumours investigated, the methods used and the number of individual point mutations tested for. It is therefore difficult to state the true number of CRCs that contain K-ras mutations.
The aims of our study were to develop validated tests for seven K-ras point mutations and to apply them in a thorough investigation of the incidence of the mutations in tumours from a large cohort of CRC patients. As part of the ARMS test validation process we used the sequencing strategy described in Materials and methods. Our initial approach to directly sequence PCR amplicons verified the ARMS result inapproximately half of the tumour DNA samples investigated. One possible explanation for this could be that the ARMS tests failed to discriminate mutated from normal sequences. The tumours were not microdissected. However, a large proportion of tumour cells relative to normal tissue was identified by histology. Assuming that the tumour cells were monoclonal for any given K-ras mutation, the ratio of mutant to normal DNA might then be expected to be relatively high. Kras is an oncogene, thus there is no reason to suppose that the normal copy of the gene should not be present in K-ras mutant tumour cells, unlike in the occurrence of allele loss with tumoursuppressor genes (Kem et al, 1989; Vogelstein et al, 1989; Fearon and Vogelstein, 1990) . Therefore, when taking into account the presence of normal DNA, the mutant sequences could actually be expected to account for only a small proportion of the total DNA of the sample and so go undetected by direct DNA sequencing. This is upheld by our observations, and we therefore concluded that direct DNA sequencing was inappropriate for substantiating the ARMS results. This was confirmed by the second stage of validation in which cloned amplicons of K-ras exon I were sequenced.
Here, the DNA sequence data gave similar results to those derived by ARMS. The results from this stage of validation therefore indicate the use of a method that will detect mutations that are underrepresented against a background of wild-type alleles. The ARMS tests described herein were validated to a sensitivity of at least one mutant ras sequence in 103 wild-type sequences. In fact, control reactions for tumour DNA analysis had routinely lower ratios of mutant to wild-type input DNA. Other groups (Ehlen and Dubeau, 1989; Stork et al, 1991; Cha et al, 1992; Hasegawa et al, 1995; Hayashi et al, 1995; Carpenter et al, 1996) have reported tests based on the same principles as the ARMS tests described here.
Detection levels of mutant ras sequences present at as low as 1 in 105 wild-type sequences have been reported (Ehlen and Dubeau, 1989; Cha et al, 1992) and 1 in 103 (this study and Carpenter et al, 1996) . This ability of the technique to detect rare mutations in a background of normal DNA demonstrates its potential role in screening or in the monitoring of residual disease.
ARMS is a simple and accurate method and has several benefits over other PCR-based mutation detection systems. Specifically, the technique does not require the use of radioisotopes or the multiple probing of immobilized PCR amplicons (McLellan et al, 1993; Breivik et al, 1994; Villa et al, 1996) or cloned PCR amplicons (Sidransky et al, 1992) . The technique avoids the DNA sequencing of single-strand conformation polymorphism products (Span et al, 1996) , a technique that could be expected to be constrained by sequence under-representation as discussed above.
Similarly, under-represented mutant sequences could go undetected using PCR in conjunction with restriction fragment length polymorphism (Chen and Viola, 1991) , which is limited to low cycle numbers for the PCR to avoid false-positive results. ARMS can be performed such that carry-over contamination is avoided (Kwok and Higuchi, 1989) , as it was in the study presented herein.
There is a severe limitation of the studies that have examined the elimination of the BstNI restriction site at codon 12 in some K-ras mutations (Levi et al, 1991; Carpenter et al, 1996) . The DNA sequencing results therefore exclude the possibility that tumour 1342 is polyclonal for more than one Kras point mutation. None of the tumours analysed were found to have more than one K-ras mutation, also the overall frequency of K-ras mutation did not increase significantly between Dukes' stages. This supports the model that K-ras mutation is a relatively early event in the progression of CRC through Dukes' stages A to C (Fearon and Vogelstein, 1990) . Because only six adenomas were included in this study, the exact timing of K-ras mutation in the adenoma to carcinoma progression was not addressed.
The value of K-ras mutations as a marker of malignancy will depend on several factors, not least being the frequency of tumours of a given tumour type, such as CRC, that carry the mutation. As this study has found the frequency of K-ras mutation to be approaching 40%, additional markers for CRC would be required for general screening purposes if all CRCs were to be identified using ARMS. Tumour genotyping tests can be used for disease staging (Hayashi et al, 1995) . However, the value of tumour genotyping for screening for CRC by the identification of DNA changes is unknown. Studies have begun to address the clinical significance of DNA testing (Oudejans et al, 1991; Sidransky et al, 1992; Bell et al, 1993; Finkelstein et al, 1993a; Hasegawa et al, 1995; Hayashi et al, 1995; Petersen, 1995; Ranaldi et al, 1995; Span et al, 1996; Villa et al, 1996) . The ARMS tests described herein have been applied for clinical purposes. The significance and the findings of these studies will be published separately. ABBREVIATIONS ARMS, amplification-refractory mutation system; CFIR, cystic fibrosis transmembrane conductance regulator; CRC, colorectal cancer; PCR, polymerase chain reaction; p.f.u., plaque-forming units technology is the subject of European patent no. 0 332 435, US patent no. 5595890 and corresponding world-wide patent property (All Zeneca Limited).
